Tag: Alofisel

Europe’s first allogeneic stem cell therapy rejected by NICE

by Selina McKee | Aug 20, 2018 | News | 0

Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.

EU clears first allogeneic stem cell therapy

by Selina McKee | Mar 26, 2018 | News | 0

TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.

Seven therapies backed for EU approval

by Selina McKee | Dec 18, 2017 | News | 0

Seven therapies have been put forward for approval in the European Union, bringing closer new options for a range of conditions including Crohn’s disease, diabetes and cancer.